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Abstract
Rationale Mania is a core feature of bipolar disorder (BD)
that traditionally is assessed using rating scales. Studies
using a new human behavioral pattern monitor (BPM)
recently demonstrated that manic BD patients exhibit a
specific profile of behavior that differs from schizophrenia
and is characterized by increased motor activity, increased
specific exploration, and perseverative locomotor patterns
as assessed by spatial d.
Objectives It was hypothesized that disrupting dopaminer-
gic homeostasis by inhibiting dopamine transporter (DAT)
function would produce a BD mania-like phenotype in
mice as assessed by the mouse BPM.
Methods We compared the spontaneous locomotor and
exploratory behavior of C57BL/6J mice treated with the
catecholamine transporter inhibitor amphetamine or the
selective DAT inhibitor GBR 12909 in the mouse BPM. We
also assessed the duration of the effect of GBR 12909 by
testing mice in the BPM for 3 h and its potential strain
dependency by testing 129/SvJ mice.
Results Amphetamine produced hyperactivity and in-
creased perseverative patterns of locomotion as reflected
in reduced spatial d values but reduced exploratory activity
in contrast to the increased exploration observed in BD
patients. GBR 12909 increased activity and reduced spatial
d in combination with increased exploratory behavior,
irrespective of inbred strain. These effects persisted for at
least 3 h.
Conclusions Thus, selectively inhibiting the DAT produced
a long-lasting cross-strain behavioral profile in mice that
was consistent with that observed in manic BD patients.
These findings support the use of selective DAT
inhibition in animal models of the impaired dopaminergic
homeostasis putatively involved in the pathophysiology of
BD mania.
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Introduction
Bipolar disorder (BD) is a severe neuropsychiatric disorder,
affecting approximately 1–2% of the population (Merikangas
et al. 2007). Mania is the cardinal feature of BD and
traditionally has been assessed using self- and observer-
rating scales. The qualitative nature of rating scales may
contribute to the paucity of animal models for BD mania
with most models being based on simple measures of
motoric hyperactivity (Einat 2006b).
Motoric hyperactivity can be induced in rodents by
manipulating numerous disparate neurotransmitter systems,
yet these stimulants can be distinguished from one another
by their differential effects on patterns of exploratory and
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Traditionally, quantitative assessments of activity, explora-
tion, and locomotor patterns have required the use of
different testing chambers, such as the open field test,
photobeam activity chambers, and holeboard tasks (Bushnell
1987; Collins et al. 1979; Fink and Smith 1979;F i t z g e r a l de t
al. 1988; Geyer et al. 1986;G o l de ta l .1988; Gould et al.
2001; Kulkarni and Dandiya 1975; Meliska and Loke 1984;
Paulus and Geyer 1992; Sessions et al. 1980). We developed
the behavioral pattern monitor (BPM) for use in rats (Geyer
et al. 1986; Paulus and Geyer 1993) and mice (Risbrough et
al. 2006). The BPM combines aspects of each of these
testing chambers, enabling quantitative multivariate assess-
ments of activity, exploration, and locomotor patterns
simultaneously. The BPM has proven to be effective in
differentiating between diverse stimulants including
amphetamine, apomorphine, caffeine, 3,4-methylenedioxy-
N-methylamphetamine, nicotine, phencyclidine, and sco-
polamine (Geyer and Paulus 1996; Geyer et al. 1986;
Paulus and Geyer 1993) .T h es a m ep r i n c i p l e so fm u l t i -
variate assessment used to differentiate stimulants in the
BPM have recently been applied to quantifying the behavior
of psychiatric inpatients in a human BPM, the development
and conception of which is described elsewhere (Young et al.
2007b). As predicted, manic BD patients exhibit increased
activity as measured by counts, distance traveled, and
acceleration. BD patients also exhibit significantly more
specific exploratory behavior than healthy comparison
subjects as measured by object interactions. Moreover,
the structure of the locomotor paths taken by BD
patients differed from comparison subjects, with BD
patients exhibiting reduced spatial d, indicative of
distance covering as opposed to localized meandering
exploration (Perry et al. 2009). Importantly, the explor-
atory profile of BD manic patients also differed consider-
ably from that of schizophrenia patients, suggesting
differing behavioral profiles dependent upon psychotic
disorder (Perry et al. 2009). Hence, there exists a detailed
quantitative assessment of behavior selective to BD
inpatients, which animal models specific to BD mania
should therefore also exhibit.
As discussed elsewhere (Geyer and Markou 2002), the
identification of an animal model of a neuropsychiatric
disorder can benefit both by comparisons with quantified
behavioral characteristics seen in the disorder and by
reference to the neural substrates that are hypothesized to
underlie the abnormal behavior. A dysregulation of dopa-
minergic homeostasis may contribute to the BD mania
profile (Manji et al. 2003; Vawter et al. 2000; Young et al.
1994). Abnormal expression of the dopamine transporter
(DAT) has been implicated in the neuropathophysiology of
BD through genetic linkage studies (Greenwood et al.
2001, 2006;K e l s o ee ta l .1996), with the functional
consequences of an observed DAT mutation leading to
reduced cell surface DAT expression (Horschitz et al.
2005). Amphetamine, which inhibits the DAT and other
monoamine transporters (Han and Gu 2006; Rothman and
Baumann 2006), is one of the most common animal models
of BD in mice (Arban et al. 2005; Gould et al. 2001), rats
(Cappeliez and Moore 1990; Frey et al. 2006; Shaldivin et
al. 2001), and humans (Asghar et al. 2003; Silverstone et al.
1998). Despite the prevalent use of amphetamine as a
model of BD, however, there has been limited success in
developing therapies specifically for BD. Indeed, most
current treatments were developed originally for other
disorders and/or resulted from serendipitous observations
(Cryan and Slattery 2007; Gould and Einat 2007). This
poor treatment development rate may be due in part to the
lack of pharmacological selectivity of the commonly used
model, amphetamine. Amphetamine exhibits approximately
a 5- to 9-fold greater affinity for the norepinephrine
transporter (NET) than the DAT, with some efficacy at
blocking serotonergic transporters also (Han and Gu 2006).
DAT knockdown (KD) mice on a 129/S background strain
exhibit a selective 90% reduction in DAT expression
(Zhuang et al. 2001). Recently, we demonstrated that DAT
KD mice exhibit a phenotype in the mouse BPM that
mimicked the profile of manic BD patients, increased
activity and specific exploration with reduced spatial d
representative of greater distance covering behavior. In
preliminary studies, acute administration of 2.5 mg/kg
amphetamine to C57BL/6J mice did not reproduce the
manic BD phenotype as reduced specific exploration was
observed (Perry et al. 2009). Acute administration of the
DAT selective inhibitor GBR 12909 (Heikkila and Manzino
1984) at 16 mg/kg, however, did produce a behavioral
profile in C57BL/6J mice that was consistent with both BD
mania patients and DAT KD mice (Perry et al. 2009). Thus,
it appeared that GBR 12909 but not the “gold standard”
mania model—amphetamine treatment—reproduced the
BD mania exploratory phenotype in C57BL/6J mice.
Based on these initial findings, the present studies were
designed to compare the full dose–response functions for
the effects of amphetamine and GBR 12909 on exploratory
behavior in C57BL/6J mice assessed in the BPM. We also
examine the time course of the effects of GBR 12909 over
3 h. Finally, we examined the cross-strain consistency of
effects of GBR 12909 by testing the same dose–response
curve in 129/SJ mice in order to compare the drug-induced
profile with the phenotype observed in DAT KD mice. We
hypothesized that selective DAT inhibition produces a
“mania-like” phenotype in mice that is independent of
strain, long lasting, and not reproduced by any tested dose
of amphetamine.
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Animals
To assess the effects of amphetamine and GBR 12909, male
C57BL/6J and 129/SvJ mice (20–40 g) were obtained from
Jackson Laboratories and tested at approximately 4 months
old. All mice were housed in groups of maximum four per
cage with a reversed day–night cycle (lights on at 8.00 P.M.,
off at 8.00 A.M.) at the University of California, San Diego
(UCSD) vivarium. The animals had unlimited access to
water and food (Harlan, Madison, WI, USA) except during
testing. Before testing, all mice were brought to the testing
room covered against exposure to light for an acclimation
period of at least 60 min. Testing occurred between
9.00 A.M. and 6.00 P.M. All of the behavioral testing
procedures were approved by the UCSD Institutional
Animal Care and Use Committee. All mice were maintained
in an animal facility that meets all federal and state require-
ments for animal care and was approved by the American
Association for Accreditation of Laboratory Animal Care.
Drugs
d-Amphetamine sulfate (Sigma, St. Louis, MO, USA) was
dissolved in saline and was administered with a 5-ml/kg
injection volume. GBR 12909 dihydrochloride (Sigma, St.
Louis, MO, USA) was dissolved in saline after sonicating
for 2–4 h at 40°C. Due to the poor solubility of GBR 12909
in saline, the injection volume was increased to 10 ml/kg.
Free-base drug weights were used in all drug calculations.
All drugs were administered by intraperitoneal injection
immediately prior to the mice being placed in the testing
chambers and data recording initiated. Saline (0.9%) was
used as vehicle in each experiment. Drug doses were based
on previous studies demonstrating increased activity and
exploration following amphetamine (Gould et al. 2001,
2007; Arban et al. 2005) and GBR 12909 treatment (van
den Buuse and de Jong 1989; Zalcman 2001).
Mouse behavioral pattern monitor
Spontaneous locomotor and exploratory behavior was
examined in ten mouse BPM chambers as described
previously (Risbrough et al. 2006). In brief, a single
chamber consists of a 30.5×61×38-cm area, with a
Plexiglas hole board floor that was equipped with floor
holes in the front, middle, and rear parts of the floor and
eight wall holes (three along each side of the long walls and
two holes in the front and back walls). Each hole is
equipped with an infrared photobeam so holepoking
behavior can be detected. The chamber is illuminated from
a single light source above the arena (producing 350 lux in
the center and 92 lux in the four corners). The location of
the mouse is obtained from a grid of 12×24 infrared
photobeams 1 cm above the floor (2.5 cm apart along the
length and the width of the chamber; 24_12 X–Y array),
recording the location of the mouse every 0.1 s, with its
position defined across nine unequal regions (four corners,
four walls and center; Geyer et al. 1986). Rearing behavior
is detected by an array of 16 infrared photobeams placed
2.5 cm above the floor and aligned with the long axis of
the chamber. At the start of each test session, mice were
placed in the bottom left-hand corner of the chamber,
facing the corner, and the test session started immedi-
ately. The primary measures of interest were activity
(transitions—movement across the defined regions),
exploratory behavior (holepoking and rearing), and
locomotor pattern (spatial d). Spatial d quantifies the
geometrical structure of the locomotor path, where a value
of 2 represents highly circumscribed small-scale move-
ments, while 1 represents straight-line distance-covering
movements. To quantify spatial d, the path length of the
animal is separated into micro-events based on successive
(x,y) coordinates to which different measuring resolutions
(k) are applied. Using a large k corresponds to a more
global depiction of movement while smaller k values
provide quantification of local events. Fitting a slope
using a least-squares straight-line approximation between
the logarithm of the values generated by these k ranges
provides the value for the spatial scaling exponent d
(Paulus and Geyer 1991).
Experiment 1: dose–response study on the effects
of amphetamine on C57BL/6J mice in the mouse BPM
This study was conducted to determine a dose–response
effect of amphetamine in C57BL/6J male mice adminis-
tered vehicle (n=6) or amphetamine at 0.5 (n=7), 1.25
(n=7), 2.5 (n=7), 5 (n=7), or 10 (n=7) mg/kg. These mice
had previously been exposed to the mouse BPM as well as
an alpha 7 nicotinic acetylcholine receptor agonist and
antagonists on two previous occasions, with >8 weeks
washout period between studies. Some data from the mice
treated with 2.5 mg/kg amphetamine were presented
previously in Perry et al. (2009). The locomotor and
behavioral activity of the mice was assessed for 60 min in
the BPM.
Experiment 2: dose–response curve of GBR 12909—effects
on C57BL/6J mice in the mouse BPM
To establish the behavioral effects of GBR 12909 in the
mouse BPM, a dose–response study was performed on
C57BL/6J mice over 60 min. Eighty male C57BL/6J mice
were assessed in the BPM after acute administration of
Psychopharmacology (2010) 208:443–454 445vehicle (n=14) or GBR 12909 at 2.85 (n=14), 5 (n=13), 9
(n=13), 16 (n=13), or 28.5 mg/kg (n=13). These mice had
previously been exposed to the mouse BPM for character-
ization purposes one time over 10 weeks previously to
current testing and were drug naïve. Some data from the
mice treated with 16 mg/kg GBR 12909 were presented
previously in Perry et al. (2009).
Experiment 3: dose–response curve of GBR 12909—effects
on 129/SvJ mice in the mouse BPM
To assess putative strain-independent effects of GBR-12909
and to compare them with the phenotype of DAT-deficient
mice on a mixed 129/SvJ-C57BL/6 background, a dose–
response study was performed in 129/SvJ mice over
60 min. A total of 60 experimentally naïve mice were
treatedacutelyimmediately prior totestinginthe mouse BPM
with vehicle (n=9) or GBR 12909 at 5 (n=8), 9 (n=8), 10.9
(n=9), 13.2 (n=9), 16 (n=9), or 28.5 mg/kg (n=8).
Experiment 4: duration of action of GBR 12909
in C57BL/6J mice in the mouse BPM
To determine the duration of action of GBR 12909, a dose–
response study was performed in C57BL/6J mice prior to a
3-h assessment of exploratory behavior in the mouse BPM.
Experimentally, naïve mice were treated acutely with
vehicle (n=8) or 9 (n=8), 16 (n=8), or 28.5 mg/kg (n=8)
GBR 12909.
Statistics
The data from each experiment were analyzed using a
mixed analysis of variance, with treatment as a between-
subject variable and time as a within-subject variable.
Significant main effects were analyzed using Tukey’s post
hoc analyses. The data were analyzed in 10- or 30-min time
bins using the Biomedical Data Programs statistical
software (Statistical Solutions Inc., Saugus, MA, USA).
The alpha level was set to 0.05.
Results
Experiment 1: amphetamine dose–response study
A dose–response curve of amphetamine was generated in
male C57BL/6J mice to assess the efficacy of amphetamine
administration as a pharmacological model of bipolar
disorder mania.
Locomotor activity A significant drug × time interaction
was observed for transitions (F(25, 170)=6.15, p<0.0001;
Fig. 1a), distance traveled (F(25, 170)=5.84, p<0.0001),
and center entries (F(25, 170)=3.31, p<0.0001). Tukey’s
post hoc analysis revealed that mice treated with 5 mg/kg
amphetamine exhibited significantly more transitions rela-
tive to vehicle (p<0.05) at time period 1. Mice administered
2.5 mg/kg amphetamine exhibited significantly more
transitions than vehicle-treated animals (p<0.05) in time
periods 2, 3, 4, 5, and 6, while mice administered 10 mg/kg
amphetamine exhibited significantly lower transitions in the
same time periods (p<0.05). A similar pattern was
observed in distance traveled, with mice given 5 mg/kg
amphetamine covering significantly greater distance than
vehicle-treated mice in time periods 1 and 2 only (p<0.05),
while mice administered 2.5 mg/kg amphetamine exhibited
greater distance traveled in every time period (p<0.05).
Mice administered 10 mg/kg amphetamine did not exhibit
reduced distance traveled in any time period, likely due to
floor effects (p>0.05), but did exhibit lower center entries
compared to vehicle control mice (p<0.05) in time periods
2 and 5.
Exploration Significant main effects of drug were
observed for holepoking behavior (F(5, 34)=11.03, p<
0.0001; Fig. 1b) and time spent in the center (F(5, 34)=
2.64, p<0.05), while a significant drug × time interaction
was observed for rearings (F(25, 170)=3.12, p<0.0001;
Fig. 1c). Post hoc analysis revealed a dose–response
effect of amphetamine significantly lowering holepoking
behavior, observed in mice administered 2.5, 5.0, and
10.0 mg/kg when compared to vehicle (p<0.05), with a
trend to lower holepoking behavior observed in 1.25 mg/
kg amphetamine-treated mice (p<0.1). Post hoc analyses
did not reveal any significant effect of any dose compared
to vehicle in center entries or rearings at any time period
(p>0.05).
Locomotor pattern A significant drug × time interaction
was observed for spatial d (F(25, 170)=4.56, p<0.0001;
Fig. 1d). Post hoc analyses indicated that mice administered
10 mg/kg amphetamine displayed higher spatial d at time
periods 3, 4, and 5 when compared to vehicle-treated mice
(p<0.05), further supporting a stereotypic effect at this
dose. Mice administered 2.5 mg/kg amphetamine, however,
displayed lower spatial d when compared to vehicle
controls (p<0.05) although only at time period 1.
Experiment 2: dose–response curve of GBR 12909—effects
on C57BL/6J mice in the mouse BPM
A dose–response study was performed with the selective
DAT inhibitor GBR 12909 (vehicle, 2.85, 5, 9, 16, and
28.5 mg/kg) in C57BL/6J mice.
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were found for transitions (F(25, 340)=10.22, p<0.0001;
Fig. 2a), distance traveled (F(25, 340)=11.06, p<0.0001),
and center entries (F(25, 340)=2.84, p<0.0001). Tukey’s
post hoc analyses for transitions revealed that mice
administered 16 and 28.5 mg/kg of GBR 12909 exhibited
higher levels of transitions (p<0.05) than vehicle-treated
mice in time periods 2 (16 mg/kg only), 3, 4, 5, and 6. The
analyses for distance traveled revealed that mice adminis-
tered 16 mg/kg GBR 12909 exhibited higher levels of
transitions (p<0.05) than vehicle-treated mice in all time
periods, while mice administered 28.5 mg/kg GBR 12909
differed from vehicle (p<0.05) in time periods 2, 3, 4, 5,
and 6. For center entries, post hoc analyses revealed that
mice administered 16 mg/kg GBR 12909 displayed higher
levels of center entries than mice administered vehicle in
time periods 2, 3, 4, 5, and 6 (p<0.05).
Exploratory behavior Significant time × drug interactions
were observed for holepoking (F(25, 340)=1.63, p<0.05;
Fig. 2b) and rearing (F(25, 340)=6.74, p<0.0001; Fig. 2c).
A nonsignificant trend effect of drug was observed for
center duration (F(5, 68)=2.32, p=0.0521) but no signifi-
cant time × drug interaction. Post hoc analyses for
holepokes revealed that during time periods 2 and 3, mice
administered 28.5 mg/kg of GBR 12909 showed lower
levels of holepoking behavior than mice administered
vehicle (p<0.05). For rearing, mice administered 16 mg/kg
GBR 12909 reared more than vehicle-treated mice in time
periods 3, 4, 5, and 6 (p<0.05).
Locomotor patterns A significant time × drug interaction
was observed for spatial d (F(25, 340)=3.61, p<0.0001;
Fig. 2d). Post hoc analyses revealed that mice administered
16 and 28.5 mg/kg GBR 12909 showed lower values of
spatial d than mice administered vehicle in time periods 3,
4, 5, and 6 (p<0.05). Mice administered 5 mg/kg had
significantly lower levels of spatial d when compared to
vehicle-treated mice in time periods 5 and 6 (p<0.05),
while mice administered 9 mg/kg GBR 12909 exhibited
lower spatial d values in time period 5 compared to vehicle
(p<0.05).
Fig. 1 Effects of amphetamine on exploratory behavior in C57BL/6J
mice in the mouse BPM. The nonselective NET and DAT inhibitor
amphetamine was administered to mice at various doses prior to their
exploration in the mouse BPM. Exploratory behavior was measured as
activity levels—transitions (a), specific exploration—holepokes (b)
and rearing (c), as well as locomotor pattern—spatial d (d). An
inverted U-shaped dose–response was observed for amphetamine
effects on activity where a low dose (2.5 mg/kg) increased activity
levels while higher dose (10 mg/kg) lowered activity levels (a). The
only effect of amphetamine on specific exploration, however, was to
reduce holepoking at all but the lowest dose (b), with no effect on
rearing (c). Consistent with activity levels, there was a separation of
effects between a low (2.5 mg/kg) and high (10 mg/kg) dose, with
some reduction in spatial d at low and increased spatial d at high doses
(d). Data presented as mean ± SEM. *p<0.05 when compared to
vehicle control
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on 129/SvJ mice in the mouse BPM
A dose–response study was performed with the selective
DAT inhibitor GBR 12909 (vehicle, 5, 9, 10.9, 13.2, 16,
and 28.5 mg/kg) in 129/SvJ mice. We hypothesized that the
effects of GBR 12909 would be similar to those seen in
C57BL/6J mice and to the phenotype of the DAT-deficient
mutant mice tested in the mouse BPM.
Locomotor activity Significant main effects of drug were
found for transitions (F(6, 53)=4.99, p<0.0005; Fig. 3a),
distance traveled (F(6, 53)=6.30, p<0.0001), and center
entries (F(6, 53)=2.54, p<0.05). Furthermore, time × drug
interactions were observed for transitions (F(30, 265)=
6.49, p<0.0001), distance traveled (F(30, 265)=6.1, p<
0.0001), and center entries (F(30, 265)=2.6, p<0.0001).
Tukey’s post hoc analyses revealed that 16 mg/kg GBR
12909 increased transitions and distance traveled when
compared with saline for time periods 2–6 and increased
center entries for time periods 3–6( p<0.05). GBR 12909 at
28.5 mg/kg increased transitions and distance traveled
when compared to saline at time periods 2–6( p<0.05,
although p<0.1 for transitions in time period 1) and
increased center entries in time periods 3 and 6 only.
Increases in transitions and distance traveled were also
observed for 13.2 and 10.9 mg/kg GBR 12909 attime periods
3–6( p<0.05), while 9 mg/kg increased transitions and
distance traveled in time periods 5 and 6 only (p<0.05).
GBR 12909 at 10.9 mg/kg also increased center entries when
compared to saline in time periods 5 and 6 (p<0.05).
Exploratory behavior For holepoking (F(6, 53)=2.90, p<
0.05; Fig. 3b) and rearing (F(6, 53)=2.59, p<0.05; Fig. 3c),
significant main effects for drug were observed. Also,
time × drug interactions were observed for holepoking (F
(30, 265)=2.0, p<0.005) and rearing (F(30, 265)=2.3, p<
0.0005). No significant effects for center duration were
found (p>0.05). Post hoc analyses of significant interac-
tions revealed for rearing that GBR 12909 at 16 and
28.5 mg/kg induced more rearing when compared to saline
in time periods 4–6( p<0.05). GBR 12909 at 28.5 mg/kg
increased holepoking in time periods 5 and 6, while 16 mg/kg
increased holepoking at time period 5, compared to saline-
treated mice (p<0.05).
Locomotor patterns A significant main effect of drug was
observed for spatial d (F(6, 53)=2.59, p<0.05; Fig. 3d),
and a trend toward a drug × time interaction was observed
(F(30, 265)=1.5, p=0.06). Post hoc analyses were per-
formed for the interaction to remain consistent with the rest
of the study. Post hoc analyses revealed that GBR 12909
lowered the value of spatial d for doses 10.9, 16, and
28.5 mg/kg when compared to saline in time periods 2, 3,
and 4, while 13.3 mg/kg GBR 12909 reduced spatial d in
time period 2 only (p<0.05).
Fig. 2 Effects of GBR 12909
on exploratory behavior in
C57BL/6J mice in the mouse
BPM. Mice were administered
various doses of the selective
DAT inhibitor GBR 12909 prior
to the assessment of their ex-
ploration in the mouse BPM.
Exploration was measured in the
BPM for activity levels—
transitions (a), exploration—
holepoking (b) and rearing (c),
as well as locomotor patterns—
spatial d (d). GBR 12909
increased activity at the highest
(16 and 28.5 mg/kg) doses
tested (a). The effects of GBR
12909 on exploration differed
by dose and measure—the
highest dose lowered
holepoking (b) while the second
highest dose increased rearing
(c). Data presented as mean ±
SEM. *p<0.05 when compared
to vehicle administered
control mice
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in C57BL/6J mice in the mouse BPM
The duration of effect of GBR 12909 was assessed by
administering multiple doses (vehicle, 9, 16, or 28.5 mg/kg)
to C57Bl/6J mice immediately prior to their assessment in
the mouse BPM for an extended period of time (3 h). We
hypothesized that GBR 12909 would exhibit long-lasting
effects on exploratory behavior.
Locomotor activity Significant main effects of drug were
observed for transitions (F(3, 32)=20.4, p<0.0001;
Fig. 4a), distance traveled (F(3, 32)=21.4, p<0.0001),
and center entries (F(3, 32)=3.2, p<0.05). Moreover,
time × drug interactions were observed for transitions (F
(15, 160)=3.7, p<0.0001), distance traveled (F(15, 160)=
4.4, p<0.0001), and center entries (F(15, 160)=2.0, p<
0.05). Tukey’s post hoc analyses revealed GBR 12909 at
all three doses increased transitions and distance traveled
at all six 30-min time intervals (p<0.05), except for 9 mg/
kg at time point 1 (p>0.05). Increased center entries were
observed following 9 mg/kg GBR 12909 at time periods 2,
2, 5, and 6, 16 mg/kg at time periods 3 and 6, and
28.5 mg/kg at time period 3 (p<0.05).
Exploratory behavior No significant main effects of drug
were observed for holepoking (Fig. 4b) or center duration,
but there was a main effect of drug on rearing (F(3, 32)=
5.0, p<0.01; Fig. 4c). Time × drug interactions were
observed, however, for holepoking (F(15, 160)=7.1, p<
0.0001), rearing (F(15, 160)=6.0, p<0.0001), and center
entries (F(15, 160)=3.1, p<0.0005). Post hoc analyses of
significant interactions revealed that 16 mg/kg GBR 12909
increased rearing at 30-min time intervals 3–6, while 9 mg/
kg increased rearing at time periods 3, 5, and 6 and
28.5 mg/kg increased rearing at time periods 5 and 6 only
(p<0.05). While 16 and 28.5 mg/kg initially decreased
pokingattimeperiod 1(p<0.05), 16 mg/kg increased poking
at time periods 5 and 6, while 9 mg/kg increased poking
in the fifth time period (p<0.05). Increased center
duration was observed for 9 mg/kg at time periods 5 and
6( p<0.05).
Fig. 3 Effects of GBR 12909 on exploratory behavior in 129/SvJ
mice in the mouse BPM. Mice (129/SvJ) were administered various
doses (5, 9, 10.9, 13.2, 16, and 28.5 mg/kg) of the selective DAT
inhibitor GBR 12909 immediately prior to the assessment of their
exploration in the mouse BPM. Exploration was measured in the BPM
for activity levels—transitions (a), exploration—holepoking (b) and
rearing (c), as well as locomotor patterns—spatial d (d). GBR 12909
increased activity at various doses tested, only 16 and 28.5 mg/kg
initially but also 9, 10.9, and 13.2 mg/kg by the end of testing (a). The
effects of GBR 12909 on exploration were similar for the two
measures, with 16 and 28.5 mg/kg increasing holepoking (b) and
rearing (c) toward the end of the test session. Doses of GBR 12909
larger than 10.9 mg/kg also lowered spatial d, although this effect was
seen predominantly between 10 and 40 min (d). Data presented as
mean ± SEM. *p<0.05 when compared to vehicle administered
control mice. Scales on the x-axes differ from Figs. 1 and 2 due to
differing basal activity levels of C57BL/6J and 129/SvJ mice
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observed for spatial d (F(3, 32)=6.1, p<0.005; Fig. 4d). A
time × drug interaction was also observed for spatial d (F
(15, 160)=12.4, p<0.005). Post hoc analyses revealed
differing effects of drug dose over the 3-h period. GBR
12909 at 16 mg/kg reduced spatial d relative to saline at
time periods 1, 3, 4, and 5, while 28.5 mg/kg reduced
spatial d only at time periods 1, 3, and 4 and 9 mg/kg
reduced spatial d only at time periods 3 and 4 (p<0.05).
Discussion
We investigated the predictive validity of two animal
models of quantified hyperexploration in BD mania. These
treatment models included the “gold standard” mixed NET/
DAT inhibitor amphetamine and the selective DAT inhibitor
GBR 12909. Amphetamine administration induced hyper-
activity, as well as reduced spatial d at low doses, consistent
with BD mania patients, with the opposite effect at high
doses. Amphetamine reduced specific exploratory activity
at multiple doses, however (Fig. 1), in contrast to manic BD
patients in the human BPM (Perry et al. 2009). Mice
administered 16 mg/kg GBR 12909, irrespective of
background strain, consistently exhibited increased activity,
reduced spatial d, and increased exploratory behavior
(Fig. 2, 3, and 4). Thus, the phenotype produced by
selectively inhibiting DAT function in the mouse BPM was
consistent with the behavior of BD patients in the human
BPM.
Amphetamine is a relatively nonselective monoamine
reuptake inhibitor, being most potent at the NET with 6–10-
fold less efficacy at DAT in rats, mice, and humans (Han
and Gu 2006; Holmes and Rutledge 1976). Although
amphetamine treatment has been a popular model with
which to assess mania (Einat 2006b; Frey et al. 2006;
Gould et al. 2001; Silverstone et al. 1998), the main
phenotype of BD modeled has been that of increased motor
activity. While lithium has been shown to reduce
amphetamine-induced hyperactivity in four out of 12 strains
of mice, this effect was observed in doses that also reduced
Fig. 4 Time course of the effects of GBR 12909 on exploratory
behavior in C57BL/6J mice in the mouse BPM. Mice were
administered the selective DAT inhibitor GBR 12909 at various doses
(9, 16, and 28.5 mg/kg) immediately prior a 3-h assessment of their
exploration in the mouse BPM. Activity levels—transitions (a),
exploration—holepoking (b) and rearing (c), as well as locomotor
patterns—spatial d (d) were all measured. GBR 12909 increased
activity at various doses tested, only 16 and 28.5 mg/kg initially but
also 9 mg/kg throughout the 3-h period (a). Despite an initial drop in
holepoking, GBR 12909 at 16 mg/kg consistently increased hole-
poking (b) and rearing (c). GBR 12909 at 16 mg/kg also consistently
lowered spatial d (d), with some modest effects at 9 and 28.5 mg/kg as
well. Data presented as mean ± SEM. *p<0.05 when compared to
vehicle administered control mice
450 Psychopharmacology (2010) 208:443–454activity levels (Gould et al. 2007). Hence, it remains
unclear whether lithium specifically ameliorated
amphetamine-induced hyperactivity. Here, we demonstrate
that while 2.5 mg/kg amphetamine produced hyperactivity,
the higher dose of 10 mg/kg significantly reduced activity
levels presumably due to the induction of competing
stereotypies (Fig. 1a). Recent studies providing quantitative
assessments of exploratory behavior in manic BD patients
have revealed a more complex phenotype, with locomotor
hyperactivity being accompanied by increased specific
exploratory interactions and reduced spatial d compared to
healthy comparison subjects (Perry et al. 2009). While
amphetamine administration lowered spatial d at certain
doses, it also significantly increased spatial d at the highest
dose. The reported effects of amphetamine on specific
exploratory behavior have been contradictory, with no
effect (Kokkinidis and Zacharko 1980), reduced holepoking/
rearing (File and Wardill 1975; Lister and File 1987), or
increased rearing (Gulley et al. 2007; Kim et al. 2000)a l l
being reported. In the present study conducted in the
mouse BPM—a direct analog of the human BPM in
which the exploratory behavior of BD patients has been
characterized—amphetamine reducedexploratory behaviorin
contrast to the behavior of manic BD patients (Fig. 1b; Perry
et al. 2009). In fact, amphetamine induced a dose-related
reduction in specific exploratory activity in the mouse BPM
as measured by hole interactions. The combined effect of
amphetamine on both NET and DAT is likely to underlie its
effect of reducing specific exploration. Manipulation of the
norepinephrine system affects exploratory activity (Flicker
and Geyer 1982; Kitchigina et al. 1997; Mansour et al. 2003;
Sara et al. 1995), with increased norepinephrine in the
synaptic cleft—which occurs following NET inhibition—
having been demonstrated to reduce exploratory behavior of
rats in the holeboard task (Sara et al. 1995). An alternative
explanation is that reduced specific exploration following
amphetamine administration was a result of the development
of stereotypic behavior. Although the reduction in activity
after administration of amphetamine at 10 mg/kg was likely
due to competing stereotypies, which also resulted in
increased spatial d (see Paulus and Geyer 1991), such
stereotypy is unlikely to have interfered with specific
exploration at low doses (1.25 and 2.5 mg/kg). In fact,
stereotypy does not appear to affect amphetamine-induced
increases in locomotor activity at doses as low as 2 mg/kg in
C57BL/6 mice (Yates et al. 2007). Thus, given that
amphetamine inhibits NET and that selective NET inhibition
can reduce specific exploration, these data support concerns
raised regarding the validity for the amphetamine
treatment model of BD in humans (Silverstone et al.
1998), rats (Cappeliez and Moore 1990;F r e ye ta l .2006),
a n dm i c e( A r b a ne ta l .2005; Gould et al. 2001). There has
been recent interest in the use of the combined amphetamine/
chlordiazepoxide treatment-induced hyperactivity as a model
of mania, first described in 1966 (Rushton and Steinberg
1966). Although not assessed in the present study and
knowledge of the effects of this model on spatial d and
specific exploration are unknown, there is some evidence
that low doses of antimanic agents can attenuate this
combined model-induced hyperactivity which do not affect
activity alone (Arban et al. 2005; Dencker et al. 2008; Vale
and Ratcliffe 1987). There is evidence, however, that the
observed attenuation of hyperactivity may not be as a result
of blockade of the combined drug effects on activity but a
chlordiazepoxide-induced potentiation of the hypolocomotor
effects of antimanic agents (Arban et al. 2005; Kelly et al.
2009). Thus, it has been suggested that this model may not
prove useful in a drug discovery process due to interpretive
difficulties (Kelly et al. 2009).
We have demonstrated that more selective inhibition of
the DAT through either genetic or pharmacological manipu-
lation did, however, increase exploration in mice as well as
inducing hyperactivity and reducing spatial d (Perry et al.
2009). Administration of GBR 12909 induced locomotor
hyperactivity consistent with amphetamine (Fig. 5). GBR
12909 at 16 mg/kg in two background strains led to a
hyperactive phenotype that differed from amphetamine but
was consistent with previous reports (Kliethermes and
Crabbe 2006; Mitchell et al. 2006; van den Buuse and de
Jong 1989). Thus, 16 mg/kg GBR 12909 also reduced
spatial d and increased specific exploration (rearing), a
phenotype consistent with that of BD patients in the human
BPM (Perry et al. 2009). The observed increase in
exploration is in concurrence (van den Buuse and de Jong
Fig. 5 Representative actigrams from each study. The movement
patterns of mice from each study are recorded and analyzed. These
figures are representative patterns of movements from mice of each
study. Patterns are from the 10–20-min time point of testing. As
shown, amphetamine (a) and GBR 12909 administered (b) mice
exhibit increased activity levels in the mouse BPM compared to their
respective controls. The increased activity also led to more straight
distance-covering behavior (lower spatial d) in these mice
Psychopharmacology (2010) 208:443–454 4511989; Zalcman 2001) and in contrast (Kliethermes and
Crabbe 2006) with previous reports, although the latter study
used WSC rather than C57BL/6J mice as in the present
studies and did not examine doses between 10 and 20 mg/kg,
where the greatest effects were observed in the present
studies. Thus, the data presented here support the selectivity
of effects of 16 mg/kg GBR 12909, with lower doses being
less effective and higher doses producing effects consistent
with amphetamine. The reduction in specific exploration
observed with the highest dose of GBR 12909 (28.5 mg/kg)
is consistent with the hypothesis that both DAT and NET
inhibition reduces exploratory behavior, as observed above
with amphetamine. Despite greater selectivity for the DAT,
GBR 12909 may inhibit the NET at this dose (Heikkila and
Manzino 1984). In support of the DAT-selective phenotype,
the present DAT inhibition studies corroborate reports of
increased activity and reduced spatial d in mice with reduced
DAT levels (Cagniard et al. 2006; Ralph-Williams et al.
2003;Z h u a n ge ta l .2001), as well as adding to observations
of increased hole interactions (Perry et al. 2009).
WhileDATKDmiceexhibitedincreasedholepoking(Perry
etal.2009), GBR 12909 induced increased rearing in C57BL/
6J and 129/SvJ mice. Given that GBR 12909 increased
holepoking and rearing in 129/SvJ mice and increased
holepoking in C57BL/6J mice after 150 min of testing
suggests that there is an interaction between GBR 12909 dose
and background strain. Previously, strain differences in
exploration have been observed in these mice. For example,
relative to 129 strains, C57BL/6J mice are notably more
active (Paulus et al. 1999) and exhibit baseline differences in
these exploratory measures (Rogers et al. 1999;T a n ga n d
Sanford 2005). The increased holepoking with time in
C57BL/6J mice could also be as a result of the effect of a
metabolite of GBR 12909. To our knowledge, the half-life of
GBR 12909 has not been studied in mice, however; thus,
it is unknown whether GBR 12909 remains active after 150
min, although many studies suggest it has a long half-life
in comparison to amphetamine (55 min in mice, 6–9hi n
humans; Cho et al. 1973; GBR 12909 equals 48–57 h in
humans, Ingwersen et al. 1993;P r e t i2000). The present
studies demonstrate, however, that by reducing DAT function
genetically or pharmacologically resulted in a behavioral
profile of increased activity, reduced spatial d, and increased
specific exploration that mimics that observed in manic BD
patients (Perry et al. 2009). Such data may prove useful in
guiding future studies investigating the neurobiological basis
for BD mania as well as potential treatment options.
Further validation of these models of BD mania is still
required, however, such as assessing treatment effects on
behavior for example, although given that antimanic treatment
does not fully treat BD mania, we would not expect a full
reversal of the GBR 12909 phenotype. Further assessment of
the cross-species translational validity of the BPM is also
required and could include amphetamine administration to
healthy patients to ascertain whether the behavioral profile
describedherefollowingamphetaminetreatmentinmicewould
be reproduced in man. This comparison may be particularly
relevantgiventhedifferencesinspaceavailabilitytotestsubject
ratio for the human and mouse BPMs. Evidence for the
suitability of GBR 12909 treatment modeling mania could also
be derived from other aspects of behavior relating to BD as
d e f i n e db yt h eDiagnostic and Statistical Manual of Mental
Disorders, Fourth Edition rating scale, such as aggression,
hedonism, hypersexuality, distractibility, reduced sleep (Einat
2006a), inattention (Young et al. 2004, 2009a), working
memory (Young et al. 2007a), and executive functioning. For
example, given the fact that GBR 12909 produces a long-
lasting effect on mice in the BPM, it would be feasible to
assess its effects on the cognitive performance of mice in tasks
that last several hours, such as the attentional set-shifting task
(Young et al. 2009b). Other relevant behaviors include
reduced sleep, increased reward values, lower anxiety, and
hyperactive behavior seen in BD and also observed in mice
carrying a mutation in the Clock gene (Roybal et al. 2007).
Since chronic administration of the mood stabilizer lithium
attenuated many of these phenotypes, these mutants may also
represent a viable animal model of BD. It would be interesting
to assess the specific exploratory phenotype of these mice in
the mouse BPM, given the quantified exploratory phenotype
we have observed in manic BD patients (Perry et al. 2009).
Future studies could also investigate the hypothesis that
it is the combined effect of amphetamine on DAT and NET
that produces a behavioral profile similar, but not fully
consistent with manic BD patients. This question could be
investigated by combining low-dose GBR 12909 treatment
with a selective NET inhibitor such as atomoxetine. Irrespec-
tive of future studies, however, the data presented here still
provide the first animal model of BD mania that is based on
the quantification of exploratory activity in these patients, thus
perhaps providing a more precise approach to develop novel
therapeutics.
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